8-KShareholder Matters

Merck & Co., Inc. 8-K Report, Shareholder Vote Results (May 29, 2025)

Filed May 29, 2025For Securities:MRK

Summary

Merck & Co., Inc. (MRK) has filed an 8-K report detailing the results of its Annual Meeting of Shareholders held on May 27, 2025. The filing primarily focuses on the voting outcomes of several key proposals presented to shareholders. All director nominees were overwhelmingly elected, indicating strong shareholder confidence in the current board's composition and leadership. Similarly, the appointment of the Company's independent registered public accounting firm for 2025 received substantial ratification. Notably, the advisory vote to approve the compensation of named executive officers also passed with significant support. However, several shareholder proposals, including those related to human rights impact assessments, tax transparency, revisiting DEI goals in executive pay, and civil liberties in advertising, did not receive majority support and were voted down. These outcomes suggest shareholders are largely aligned with the company's current governance and executive compensation practices, while also signaling a divergence of opinion on specific ESG-related initiatives proposed by shareholders.

Key Highlights

  • 1All director nominees were overwhelmingly elected to the Board of Directors with a significant majority of 'For' votes.
  • 2Shareholders approved the ratification of the Company's independent registered public accounting firm for 2025 with broad support.
  • 3The non-binding advisory vote to approve the compensation of named executive officers received substantial shareholder approval.
  • 4Shareholder proposals concerning a human rights impact assessment, tax transparency report, revisiting DEI goals in executive pay, and a report on civil liberties in advertising services all failed to achieve majority shareholder support.
  • 5The consistent large number of broker non-votes across all proposals, particularly for shareholder-initiated items, suggests that a substantial portion of shares held by nominees did not have voting instructions for these specific matters.

Frequently Asked Questions

The primary outcomes of Merck's Annual Meeting shareholder vote were the overwhelming election of all director nominees, the ratification of the independent auditor for 2025, and the approval of executive compensation through an advisory vote. Conversely, several shareholder proposals, including those related to human rights, tax transparency, DEI goals in executive pay, and civil liberties in advertising, did not pass.

Yes, the non-binding advisory vote to approve the compensation of Merck's named executive officers received significant support from shareholders, with over 1.67 billion votes in favor.

These shareholder proposals failed because they did not receive a majority of the votes cast. For instance, the human rights impact assessment proposal received approximately 279 million 'For' votes compared to over 1.5 billion 'Against' votes. The outcomes suggest that a majority of voting shareholders did not support the adoption of these specific initiatives at this time.

There were 302,387,312 broker non-votes recorded for most of the proposals. This indicates that a substantial portion of shares held by nominees (brokers, banks, etc.) did not have voting instructions from the beneficial owners for these specific items. This is common for non-routine proposals, such as shareholder-sponsored resolutions, and means these shares were not counted towards the 'votes cast' for or against those proposals.